SINOPHARM (01099): China National Medicines Corporation (600511.SH) reported a net profit attributable to shareholders of 949 million yuan in the first half of the year, a decrease of 5.19% compared to the same period last year.
The China National Pharmaceutical Group Corporation released the performance of its subsidiary China National Pharmaceutical Group Co., Ltd (600511.SH) in the first half of 2025.
SINOPHARM (01099) announced the performance of its subsidiary China National Medicines Corporation (600511.SH) in the first half of 2025, with operating income of approximately 25.634 billion yuan, an increase of 3.54% year-on-year. Net profit attributable to shareholders of the listed company was approximately 949 million yuan, a decrease of 5.19% year-on-year. Basic earnings per share were 1.2572 yuan.
Related Articles
US Stock Market Move | Target Corporation (TGT.US) falls more than 7% as "CEO internal succession" plan disappoints the market.
Asian Capital "Looking Inwards": China and India Lead the Way, $22 Trillion Market Hides These Opportunities
US Stock Market Move | Some of the holders of shares are short-term support. SharpLink Gaming (SBET.US) rose more than 5.7%.
US Stock Market Move | Target Corporation (TGT.US) falls more than 7% as "CEO internal succession" plan disappoints the market.
Asian Capital "Looking Inwards": China and India Lead the Way, $22 Trillion Market Hides These Opportunities
US Stock Market Move | Some of the holders of shares are short-term support. SharpLink Gaming (SBET.US) rose more than 5.7%.
RECOMMEND
U.S. Tariff Revenue Set to Top $300 Billion This Year? Treasury Secretary Emphasizes Debt Repayment
20/08/2025
Weekend Shake-Up: Trump Administration Abruptly Expands Steel and Aluminum Tariff Scope, U.S. Importers Struggle to Comply
20/08/2025
H20 Still Under Scrutiny as NVIDIA Prepares New China-Specific Chip
20/08/2025
